 Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017322
|
| MeSH Number(s) |
E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2007 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 4 | 4 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 8 | 8 | | 2020 | 0 | 3 | 3 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 7 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Borgers JSW, Burgers FH, Terveer EM, van Leerdam ME, Korse CM, Kessels R, Flohil CC, Blank CU, Schumacher TN, van Dijk M, Henderickx JGE, Keller JJ, Verspaget HW, Kuijper EJ, Haanen JBAG. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial. BMC Cancer. 2022 Dec 30; 22(1):1366.
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
-
Judge DP, Lakdawala NK, Taylor MRG, Mestroni L, Li H, Oliver C, Angeli FS, Lee PA, MacRae CA. Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
-
Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug; 33(5):2605-2613.
-
Laetsch TW, Maude SL, Balduzzi A, Rives S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R, Grupp SA. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022 06; 36(6):1508-1515.
-
O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967.
-
Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respir Res. 2022 Jan; 9(1).
-
Georas SN, Wright RJ, Ivanova A, Israel E, LaVange LM, Akuthota P, Carr TF, Denlinger LC, Fajt ML, Kumar R, O'Neal WK, Phipatanakul W, Szefler SJ, Aronica MA, Bacharier LB, Burbank AJ, Castro M, Crotty Alexander L, Bamdad J, Cardet JC, Comhair SAA, Covar RA, DiMango EA, Erwin K, Erzurum SC, Fahy JV, Gaffin JM, Gaston B, Gerald LB, Hoffman EA, Holguin F, Jackson DJ, James J, Jarjour NN, Kenyon NJ, Khatri S, Kirwan JP, Kraft M, Krishnan JA, Liu AH, Liu MC, Marquis MA, Martinez F, Mey J, Moore WC, Moy JN, Ortega VE, Peden DB, Pennington E, Peters MC, Ross K, Sanchez M, Smith LJ, Sorkness RL, Wechsler ME, Wenzel SE, White SR, Zein J, Zeki AA, Noel P. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022 02; 149(2):488-516.e9.
-
Siu HWD, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, Segelov E, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer. 2021 Aug 18; 21(1):932.
-
Vogelmeier CF, Fuhlbrigge A, Jauhiainen A, Scheepers LEJM, Bengtsson T, Peterson S, Karlsson N, Sethi T, Locantore N, Tal-Singer R, Rennard S, Fager?s M, Da Silva CA. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respir Med. 2020 11; 173:106175.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|